Organisation paid for research Program year 2022 Source: CMS Open Payments

Va Oncology Associates

Neither a doctor nor a teaching hospital

Research payments

$80,886

137 payments

Through program year 2022, Va Oncology Associates is reported as receiving $80,886 in research payments, across 137 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2022	Research	$34,205	44
2021	Research	$46,610	92
2020	Research	$71	1

Breakdown

Who paid Research payments · program years 2020–2022

Janssen Research & Development, LLC $80,815 136 payments
Amgen Inc. $71 1 payment

Studies the money was for Research payments · program years 2020–2022

Biomarker Study to Determine Frequency of DNA repair Defects in Men with Metastatic Prostate Cancer $29,589 77 payments
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant $20,120 31 payments
Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations $13,830 21 payments
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC $9,626 6 payments
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castrat $7,650 1 payment
AMG 510_Ph3 NSCLC Monotherapy Comparator Trial $71 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.